Effect of Vitamin Supplementation in Glaucoma Patients

Devogelaere Vision26 enrolled

Overview

The impact of targeted vitamin supplementation on retinal venous pressure (RVP) and steady state pattern ERG (SSpERG) in patients with RVP 15mmHg or more above intra-ocular pressure (IOP) and serum homocystein 12µmol/l or more, with signs of progression in spite of adequate IOP control, as evidenced by SSpERG abnormality with or without structural progression or visual field progression,

Provided the inclusion criteria were met, RVP measurement was repeated, and a 1 capsule/day regimen of Ocufolin® forte was subsequently carried out for a duration of 3 months, after which repeat measurements of IOP, SSpERG, and RVP were performed, along with dilated fundoscopy. .

Study Type

OBSERVATIONAL

Enrollment

Conditions

Glaucoma Homocysteinemia Elevated Retinal Venous Pressure Abnormal Steady State Pattern Electroretinography

Interventions

Ocufolin forteDIETARY_SUPPLEMENT

start of ocufolin forte 1 dd after RVP measurement, till 90 tablets are finished (3 months)

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * glaucoma and/or ocular vascular disease in at least on eye * abnormal SSpERG * RVP measured using an ophthalmodynamometer at least 15 mmHg higher than intra-ocular pressure (IOP), * fasting serum Hcy level \> 12 µmol/l * stable and well-controlled IOP (with or without IOP-lowering treatment) Exclusion Criteria: * starting other systemic or ocular medications with potential impacts on RVP within a month before entering the study or during the course of the study * starting or changing the dosage of other medications with potential impact on SSpERG within 3 months before entering the study or during the course of the study * non-adherence to the follow-up schedule * inability to perform a proper RVP measurement using ophthalmodynamometry.

Locations (1)

Devogelaere Vision

Oudenburg, Belgium

Outcomes

Primary Outcomes

RVP effect

measurement of RVP lowering effect

Time frame: 3 months

SSpERG effect

measurement of improvement of SSpERG

Time frame: 3 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.